Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Psychiatry Research

Volumn 175, Issue 1-2, 2010, Pages 58-62

  Jaeger, Matthias ^a   Rossler, Wulf ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Adherence; Depot treatment; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTITUDE TO HEALTH; COMPARATIVE STUDY; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG INFORMATION; EARLY INTERVENTION; FAMILY ATTITUDE; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMATION DISSEMINATION; INJECTION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT AUTONOMY; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURED QUESTIONNAIRE; TREATMENT PLANNING; TREATMENT REFUSAL;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHIATRY; QUESTIONNAIRES;

EID: 72049091199     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.11.003     Document Type: Article

References (26)

1. Babiker I.E. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. Journal of Clinical Psychiatry 48 (1987) 94-97
2. Buckley P.F., Wirshing D.A., Bhushan P., Pierre J.M., Resnick S.A., and Wirshing W.C. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 21 (2007) 129-141
3. Cahn W., van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Caspers E., Laponder D.A., and Kahn R.S. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. The British Journal of Psychiatry 189 (2006) 381-382
4. Davis J.M., Matalon L., Watanabe M.D., Blake L., and Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 47 (1994) 741-773
5. Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatrica Scandinavica Supplementum 382 (1994) 28-32
6. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. International Clinical Psychopharmacology 9 Suppl 5 (1995) 17-20
7. Glazer W.M., and Kane J.M. Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry 53 (1992) 426-433
8. Harrison G., Hopper K., Craig T., Laska E., Siegel C., Wanderling J., Dube K.C., Ganev K., Giel R., an der Heiden W., Holmberg S.K., Janca A., Lee P.W., Leon C.A., Malhotra S., Marsella A.J., Nakane Y., Sartorius N., Shen Y., Skoda C., Thara R., Tsirkin S.J., Varma V.K., Walsh D., and Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. The British Journal of Psychiatry 178 (2001) 506-517
9. Heres S., Hamann J., Kissling W., and Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. Journal of Clinical Psychiatry 67 (2006) 1948-1953
10. Heres S., Schmitz F.S., Leucht S., and Pajonk F.G. The attitude of patients towards antipsychotic depot treatment. International Clinical Psychopharmacology 22 (2007) 275-282
11. Hill S.K., Schuepbach D., Herbener E.S., Keshavan M.S., and Sweeney J.A. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophrenia Research 68 (2004) 49-63
12. Hogan T.P., Awad A.G., and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 13 (1983) 177-183
13. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., Gaebel W., Gerlach J., Guelfi J.D., Kissling W., Lapierre Y.D., Lindstrom E., Mendlewicz J., Racagni G., Carulla L.S., and Schooler N.R. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. European Neuropsychopharmacology 8 (1998) 55-66
14. Lambert T., Brennan A., Castle D., Kelly D.L., and Conley R.R. Perception of depot antipsychotics by mental health professionals. Journal of Psychiatric Practice 9 (2003) 252-260
15. Naber D., and Karow A. Good tolerability equals good results: the patient's perspective. European Neuropsychopharmacology 11 Supplementum 4 (2001) S391-396
16. Nordt C., Rossler W., and Lauber C. Attitudes of mental health professionals toward people with schizophrenia and major depression. Schizophrenia Bulletin 32 (2006) 709-714
17. Patel M.X., and David A.S. Why aren't depot antipsychotics prescribed more often and what can be done about it?. Advances in Psychiatric Treatment 11 (2005) 203-211
18. Patel M.X., Nikolaou V., and David A.S. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine 33 (2003) 83-89
19. Pereira S., and Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatrica Scandinavica 95 (1997) 464-468
20. Skinner T.C., Barnard K., Cradock S., and Parkin T. Patient and professional accuracy of recalled treatment decisions in out-patient consultations. Diabetic Medicine 24 (2007) 557-560
21. Svedberg B., Backenroth-Ohsako G., and Lutzen K. On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. International Journal of Mental Health Nursing 12 (2003) 110-118
22. Taylor D.M., Young C.L., Mace S., and Patel M.X. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. Journal of Clinical Psychiatry 65 (2004) 1076-1083
23. van Haren N.E., Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., and Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biological Psychiatry 63 (2008) 106-113
24. Walburn J., Gray R., Gournay K., Quraishi S., and David A.S. Systematic review of patient and nurse attitudes to depot antipsychotic medication. The British Journal of Psychiatry 179 (2001) 300-307
25. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin 21 (1995) 419-429
26. Wiersma D., Nienhuis F.J., Slooff C.J., and Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophrenia Bulletin 24 (1998) 75-85